AJ
Highly rated in
17
conditions

Dr. Amir A. Jazaeri

Physicians Referral Service
Houston, TX
Highly rated in
17
conditions
Specialties:Obstetrics and Gynecology | Gynecologic Oncology
Experience:27 Years
Clinical Trials:Currently Recruiting for 6 Trials
Accepts:New PatientsMedicare
Highly rated in
17
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Amir A. Jazaeri's experience treating your condition:
About Dr. Amir A. Jazaeri

Amir Jazaeri is an Obstetrics and Gynecologist and a Gynecologic Oncologist in Houston, Texas. Jazaeri has been practicing medicine for over 27 years and is highly rated in 17 conditions, according to our data. His top areas of expertise are Ovarian Cancer, Ovarian Carcinosarcoma, Endometrial Cancer, Oophorectomy, and Hysterectomy. He is licensed to treat patients in Texas and Virginia. Jazaeri is currently accepting new patients.

His clinical research consists of co-authoring 78 peer reviewed articles and participating in 27 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Amir A. Jazaeri it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Amir A. Jazaeri accepts the following insurance:

  •  Blue Cross Blue Shield
  •  Ambetter
  •  Community Health
Locations
1515 Holcombe Blvd, Houston, TX 77030
Background & Education
Graduate Institution
University Of Virginia School Of Medicine, 1996
Specialties
Obstetrics and Gynecology
Gynecologic Oncology
Licenses
Obstetrics & Gynecology in VA
Hospital Affiliations
UTMB - Texas Department Of Criminal Justice Hospital
University Of Texas MD Anderson Cancer Center
Languages Spoken
English
Farsi
Persian
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
Enrollment Status: Recruiting
Publish Date: July 22, 2022
Intervention Type: Biological
Study Drugs: DurvalumabTremelimumab
Study Phase: Phase 2
Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
Enrollment Status: Recruiting
Publish Date: January 15, 2021
Intervention Type: Drug
Study Drugs: GRN-300 SIK InhibitorPaclitaxel
Study Phase: Phase 1
Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Enrollment Status: Recruiting
Publish Date: August 05, 2022
Intervention Type: Other, Biological, Drug
Study Drugs: AldesleukinCyclophosphamideFludarabineIpilimumabNivolumabLN-145 Autologous Tumor-Infiltrating LymphocytesLN-145-S1 Autologous Tumor-Infiltrating Lymphocytes
Study Phase: Phase 2
Immunomodulation of the Tumor Microenvironment in High-Grade Serous Ovarian Cancer Patients Receiving Pembrolizumab and Lenvatinib Monotherapy and Combination Therapy
Enrollment Status: Recruiting
Publish Date: July 12, 2022
Intervention Type: Drug, Biological
Study Drugs: LenvatinibPembrolizumab
Study Phase: Phase 2
A Phase II Investigation of Bevacizumab for the Treatment of Second-Look Positive Epithelial Ovarian Cancer
Enrollment Status: Recruiting
Publish Date: January 04, 2022
Intervention Type: Drug
Study Drug: Bevacizumab
Study Phase: Phase 2
Evaluation of Safety and Immunogenicity of a Peptide Vaccine in Patients With Epithelial Ovarian or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: June 20, 2014
Intervention Type: Biological, Procedure
Study Phase: Phase 1
Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic Cancers
Enrollment Status: Active, not recruiting
Publish Date: June 23, 2022
Intervention Type: Biological, Other
Study Drugs: IpilimumabNivolumab
Study Phase: Phase 1
A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
Enrollment Status: Active, not recruiting
Publish Date: December 07, 2022
Intervention Type: Drug
Study Drugs: FulvestrantAbemaciclib
Study Phase: Phase 2
Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer
Enrollment Status: Active, not recruiting
Publish Date: October 24, 2022
Intervention Type: Drug, Other, Biological
Study Drugs: CarboplatinPaclitaxelPembrolizumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Enrollment Status: Active, not recruiting
Publish Date: May 26, 2022
Intervention Type: Biological
Study Drug: Vigil
Study Phase: Phase 2
Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Enrollment Status: Active, not recruiting
Publish Date: September 26, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Autologous tumor infiltrating lymphocytes MDA-TILCyclophosphamideFludarabineInterleukin-2
Study Phase: Phase 2
A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
Enrollment Status: Completed
Publish Date: June 27, 2019
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Randomized Phase I/II Study of AVB-S6-500 in Combination With Durvalumab (MEDI4736) in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
Enrollment Status: Active, not recruiting
Publish Date: December 09, 2022
Intervention Type: Biological, Drug
Study Drugs: BatiraxceptDurvalumab
Study Phase: Phase 1/Phase 2
Pilot Study of the Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer
Enrollment Status: Withdrawn
Publish Date: March 12, 2019
Intervention Type: Drug, Other, Biological
Study Phase: Phase 2
Randomized Phase 2 Clinical Trial of Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 in Patients With Recurrent Ovarian Cancer
Enrollment Status: Not yet recruiting
Publish Date: September 28, 2022
Intervention Type: Other, Biological
Study Drugs: Anti-CD40 Agonist Monoclonal Antibody CDX-1140BevacizumabPembrolizumab
Study Phase: Phase 2
Phase I/Ib Study of Adoptive Cellular Therapy Using Autologous IL-21-Primed CD8+ Tumor Antigen-Specific T Cells in Combination With Utomilumab (PF-05082566) in Patients With Platinum Resistant Ovarian Cancer
Enrollment Status: Active, not recruiting
Publish Date: September 23, 2022
Intervention Type: Drug, Procedure, Biological
Study Drugs: AldesleukinCyclophosphamideUtomilumabCD8-Positive T Lymphocyte Infusion
Study Phase: Phase 1
View 11 Less Clinical Trials -
78 Total Publications
Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression.
Journal: Gynecologic oncology
Published: August 27, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
KS
Kathleen M. Schmeler
Dr. Kathleen M. Schmeler
Gynecologic Oncology | Obstetrics and Gynecology
Highly rated in
16
conditions
Gynecologic Oncology
Obstetrics and Gynecology

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd, 
Houston, TX 

Kathleen Schmeler is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Houston, Texas. Schmeler has been practicing medicine for over 23 years and is highly rated in 16 conditions, according to our data. Her top areas of expertise are Cervical Cancer, Endometrial Cancer, Cervical Dysplasia, Hysterectomy, and Endoscopy. She is licensed to treat patients in Texas. Schmeler is currently accepting new patients.

SW
Dr. Shannon N. Westin
Gynecologic Oncology | Obstetrics and Gynecology
Highly rated in
19
conditions
Gynecologic Oncology
Obstetrics and Gynecology

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd, 
Houston, TX 

Shannon Westin is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Houston, Texas. Westin has been practicing medicine for over 21 years and is highly rated in 19 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Testicular Yolk Sac Tumor, Hysterectomy, and Oophorectomy. She is licensed to treat patients in Texas. Westin is currently accepting new patients.

KL
Dr. Karen H. Lu
Gynecologic Oncology | Obstetrics and Gynecology
Highly rated in
17
conditions
Gynecologic Oncology
Obstetrics and Gynecology

University of Texas System

Physicians Referral Service

1515 Holcombe Blvd, 
Houston, TX 

Karen Lu is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Houston, Texas. Lu has been practicing medicine for over 32 years and is highly rated in 17 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Salpingo-Oophorectomy, and Oophorectomy. She is licensed to treat patients in Texas. Lu is currently accepting new patients.